Shanghai AbelZeta Ltd. — Biomedical Watch V2

Traitements5programmes

Essais4liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Armored and GPC3-targeted autologous CAR T-cellThis single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.	SEP	Phase 1/2		China	À vérifier
C-CAR031A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.	SEP	Phase 1	À vérifier	China	À vérifier
C-CAR031A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.	SEP	Phase 1	Thérapie cellulaire + Immunomodulation	China	À vérifier
C-CAR031A study that aimed to assess the safety and anti-tumor activity of CCAR031 injection in unresectable HCC patients.	SEP	Phase 1	À vérifier	China	À vérifier
Armored and GPC3-targeted autologous CAR T-cellThis single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+ advanced/recurrent HCC, who have progressed or are intolerant to at least two prior lines of standardized systemic therapy, and lack of other effective treatments.	SEP	Phase 1/2		China	À vérifier

Essais cliniques

4

Molécule	Indication / population	Phase	NCT	Titre	Statut
Prizloncabtagene Autoleucel	SEP	Phase 1/2	NCT05800977	ELEVATION — A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma	RECRUITING
Armored and GPC3-targeted autologous CAR T-cell	SEP	Phase 1/2	NCT06590246	A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)	ACTIVE_NOT_RECRUITING
C-CAR031	SEP	Phase 1	NCT07444281	An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung Cancer	RECRUITING
C-CAR031	SEP	Phase 1	NCT05155189	A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.